Short answer
Entrada Therapeutics, Inc. (TRDA) filed an 8-K current report with the SEC on June 10, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 5.07 (Submission of Matters to a Vote of Security Holders). Entrada Therapeutics held its 2026 Annual Meeting virtually on June 10, 2026.
Entrada Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Entrada Therapeutics held its 2026 Annual Meeting virtually on June 10, 2026
- The filing’s Item 5.02 heading indicates director elections or officer appointments and compensation matters addressed at the meeting
Item 5.07 · Submission of Matters to a Vote of Security Holders
- Annual meeting quorum established with 33,190,234 shares represented out of 38,820,616 outstanding
- Peter S. Kim and Bernhardt Zeiher elected Class II directors through the 2029 annual meeting
- Ernst & Young ratified as independent auditor for fiscal 2026 with 33,132,550 votes for
- 2021 Plan Amendment approved with 14,686,713 votes for, expanding authorized equity compensation capacity
- 2021 ESPP Amendment approved with 16,780,217 votes for, supporting continued employee stock-purchase benefits
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Entrada Therapeutics, Inc. 8-K filings
Get the next TRDA 8-K as it lands
Follow TRDA for push alerts, or ask the research agent what this filing means.